Drug Database
AL

albumin (Zenalb)

✓ Approved

Kedrion · Cell-based Therapies · Cell-based Therapies

What is albumin?

albumin is a cell-based therapies developed by Kedrion. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesZenalb
CompanyKedrion
Drug ClassCell-based Therapies
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Kedrion

Therapeutic Indications

albumin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Vascular disordersThrombosis✓ Approved

Related Research Articles

PubMedCurrent opinion in critical care2026-08-30

Albumin and the kidney, a friend or foe.

Shehabi Yahya Y, Balachandran Mayurathan M, Glassford Neil N

Albumin preparations are the most common colloids used in critically ill patients worldwide. This review is to provide the physiological rationale and evidence for benefits and harms in different clinical settings. There is a strong physiological rationale for intravenous albumin administration in critically ill patients. Iso-oncotic and hyperoncotic albumin have both been used for volume resuscitation and to maintain effective plasma volume at an optimal fluid balance. This practice, however, has not proven to be superior to using crystalloids or balanced solutions with no significant reduction in kidney injury or time on vasopressors. In patients with septic shock and hypoalbuminaemia, albeit limitations, subgroup analysis of a randomized trial suggested reduced mortality with albumin supplementation. Similarly, guidelines strongly recommend the use of albumin in hepatic-induced kidney injury and hepatorenal syndrome. Albumin also improved diuresis when combined with diuretics and may improve intradialytic hypotension. Conversely, hyperoncotic albumin infusion increased the risk of kidney injury and red cell transfusion in high-risk cardiac surgery. Hyperoncotic, and albumin administration in general, is a double-edged sword, its use should be tailored to specific clinical scenarios. The use of hyperoncotic albumin in high-risk cardiac surgery should be discouraged.

PMID 42669183
Read full article →
PubMedEuropean heart journal2026-08-30

Adrenomedullin system dysregulation predicts cardiogenic shock and mortality in acute coronary syndromes.

Wang Yifan Y, Danchin Nicolas N, Simon Tabassome T, Zeller Marianne M et al.

Cardiogenic shock (CS) is the most dreadful complication of acute coronary syndromes (ACS). Endothelial dysfunction and vascular leakage are hallmarks of CS pathophysiology; however, biomarkers reflecting these early processes are lacking. The adrenomedullin (ADM) system-the inactive precursor glycine-extended ADM (ADM-Gly), the activating enzyme peptidylglycine α-amidating monooxygenase (PAM), and biologically active ADM (bio-ADM)-modulates vascular tone and permeability. This study investigated associations of ADM system components with CS and 1-year mortality risk after ACS. ADM-Gly, PAM, and bio-ADM were assessed in 4098 (Switzerland; SPUM-ACS) and 824 (France; FAST-MI) ACS patients without CS on admission. The primary endpoint was in-hospital CS; the secondary endpoint was 1-year mortality. Biomarker-outcome associations were analysed using multivariable-adjusted regression models, and the incremental predictive value beyond established risk scores was quantified. Higher ADM-Gly and bio-ADM, but not PAM, were associated with systemic inflammation and haemodynamic compromise. ADM-Gly and bio-ADM independently predicted CS risk in Switzerland (adjusted odds ratio [aOR] per log2 increase, 1.44, 95% confidence interval [CI] 1.22-1.71, P < .001 and aOR 1.37, 95% CI 1.10-1.70, P = .004) and France (adjusted risk ratio [RR] per log2 increase, 1.82, 95% CI 1.34-2.48, P < .001 and aRR 1.55, 95% CI 1.15-2.10, P = .004), and were associated with 1-year mortality risk (adjusted hazard ratio [aHR] per log2 increase, 1.33, 95% CI 1.09-1.61, P = .005 and aHR 1.46, 95% CI 1.15-1.86, P = .002). Addition of ADM-Gly and bio-ADM to the ORBI risk score improved its discrimination (Δ area under the receiver operating characteristic curve 0.02), reclassification (net reclassification improvement 0.229), and model fit (Δ Akaike information criterion -26.9), with consistent results in external validation. ADM-Gly and bio-ADM, but not PAM, independently predict in-hospital CS and 1-year mortality risk in initially stable patients with ACS and improve early risk stratification.

PMID 42668424
Read full article →
PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-08-30

Regulating Cells Fate and Function to Facilitate Bone Regeneration via Designing Programmable Bio-Interactive Materials.

Fan Qingrui Q, Cao Fuming F, Mao Junqiang J, Yin Pengbin P et al.

Achieving efficient bone repair necessitates a thorough understanding of the physiological activities of native bone tissue, enabling selection and design of appropriate materials. To date, artificial scaffolds have been developed from inert materials to bioactive materials and demonstrate the capabilities to promote bone repair. However, the complex physiological changes that occur during bone repair pose significant challenges to their practical clinical applications. In this Review, we summarize the studies of bone biology and the evolution of materials design in the context of bone-tissue engineering applications. Specifically, we emphasize the role of biomaterials from a materials science perspective in regulating cell fates. Furthermore, we introduce the concept of programmable bio-interactive materials as a potential solution for bone regeneration. These materials possess the ability to dynamically and precisely interact with biological systems, guiding the bone-tissue regeneration process. Additionally, we discuss the unmet needs and current challenges faced in the development of bio-interactive materials for bone-tissue regeneration. By highlighting emerging strategies in the field, we aim to shed light on future directions for research and development in this exciting area of study.

PMID 42669154
Read full article →
PubMedFood chemistry: X2026-08-30

Effect of solid-state fermentation on the release and antioxidant activity of soluble polyphenols from wheat bran.

Tian Xiaomin X, Guo Yuqiu Y, Sun Linlin L, Chen Lirong L et al.

Using wheat bran as substrate, four solid-state fermentation methods were compared for soluble polyphenol release. The effect of Bio-enzymatic synergy (BES) is the most significant, producing 4.85 mg GAE/g of total phenolic substances, which is 45.77% higher than the control group (CK). LC-MS analysis revealed that ferulamide and 2,4,6-trihydroxybenzoic acid predominated in positive ion mode, while salicylic acid dominated in negative mode. Notably, salicylic acid was found almost exclusively in ester-bound and glycoside-bound fractions (>88%), indicating its release requires cleavage of covalent linkages to cell wall components. The release of salicylic acid results from the synergistic action of Bio-enzymatic synergy and alkaline hydrolysis. Both in vitro and in vivo assays confirmed that BES-released polyphenols enhanced antioxidant activity, reducing ROS and MDA levels while increasing GSH-Px activity and extending C. elegans lifespan. These findings provide a mechanistic basis for developing targeted fermentation-enzymatic processes to produce functional wheat bran extracts.

PMID 42668496
Read full article →
PubMedBiological & pharmaceutical bulletin2026-08-30

Association of Pretreatment Hepatic Function Markers with Clazosentan-Associated Fluid Retention in Patients with Subarachnoid Hemorrhage.

Oguni Kinuka K, Sogawa Rintaro R, Nakano Yuki Y, Tobita Shuko S et al.

Clazosentan is used to prevent cerebral vasospasm after aneurysmal subarachnoid hemorrhage (SAH), but it is often associated with fluid retention-related adverse events. This retrospective study investigated the relationship between the pretreatment Albumin-Bilirubin (ALBI) score and clazosentan-associated fluid retention in patients with SAH. Patients who newly initiated clazosentan treatment at Saga University Hospital between April 2022 and March 2026 were enrolled. Clinical characteristics and laboratory data were retrospectively obtained from electronic medical records. Patients were divided into fluid retention and non-fluid retention groups, and factors associated with fluid retention were analyzed. A total of 61 patients were included, with clazosentan-associated fluid retention observed in 32 patients (52.5%). The ALBI score was significantly higher (i.e., less negative) in the fluid retention group than in the non-fluid retention group (median: -2.62 vs. -2.94, p = 0.007). Multivariate logistic regression analysis revealed that an elevated ALBI score was independently associated with fluid retention (odds ratio per 0.1-point increase: 1.17; 95% confidence interval: 1.01-1.37; p = 0.03). Additionally, patients requiring loop diuretics for fluid management had significantly higher ALBI scores than those not requiring them (median: -2.61 vs. -2.91; p = 0.006). These findings suggest that an elevated pretreatment ALBI score may be linked to an increased risk of clazosentan-associated fluid retention. Further validation in patients with varying degrees of hepatic function is warranted to establish its clinical utility.

PMID 42669484
Read full article →
PubMedFood chemistry2026-08-30

Modulation of gluten network structure, dough rheology, and Chinese steamed bread quality by wheat bran albumin through molecular interactions with gluten proteins.

Zhang Lili L, Guo Fuzhen F, Bian Ke K, Zhang Tingjing T et al.

Impacts of wheat bran albumin (WBA) upon dough rheological properties alongside Chinese steamed bread quality were investigated, with emphasis on its interactions with gluten proteins and gluten network formation. WBA reduced dough viscoelasticity while significantly enhancing extensibility up to 85% with only 0.6% WBA addition, resulting in a 28.4% increase in specific volume of steamed bread. Molecular structure analysis revealed WBA induced gluten protein disaggregation by disrupting disulfide bonds in glutenin, and concomitantly promoted the aggregation through newly formed disulfide bonds and dityrosine cross-links involving gliadin subunits. These corresponded well with the increased endpoints rate and junction density of gluten network. At WBA addition ≤0.6%, protein aggregation predominated, accompanied by synergistically enhanced hydrophobic and hydrogen bonds interactions, together with super alterations in protein secondary and tertiary conformations. Overall, WBA, as a non-gluten protein, exhibited strong potential to regulate gluten network structure and improve flour processing performance.

PMID 42669276
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about albumin